RXi Obtains License to RNAi Delivery Technology From UMass Medical School

Xconomy Boston — 

RXi Pharmaceuticals, a Worcester, MA-based developer of drugs based on RNA interference technology, said today it has obtained an exclusive worldwide license to certain technology for oral delivery of RNAi drugs. The technology was developed by Michael Czech and Gary Ostroff at the University of Massachusetts Medical School. Financial terms were not disclosed.